Protein kinase C alpha (PKC-α) (PKC-α)

Protein kinase C alpha (PKC-α) is a member of the conventional subfamily of serine/threonine protein kinases, characterized by its dependence on calcium and diacylglycerol (DAG) for activation [1, 2, 3]. It is ubiquitously expressed and plays a central role in diverse cellular signaling pathways, including those governing cell proliferation, apoptosis, differentiation, and motility [1, 10, 13]. In the cardiovascular system, PKC-α is a key regulator of cardiac contractility and hypertrophy, while in the immune system, it modulates inflammatory responses and platelet activation [1, 2, 4, 12]. Its role in disease is complex and context-dependent; it acts as a tumor promoter in certain cancers, such as glioma and bladder cancer, by driving cell survival and invasion, but can function as a tumor suppressor in others [2, 10, 15]. Therapeutic strategies targeting PKC-α include small-molecule ATP-competitive inhibitors, antisense oligonucleotides, and modulators of its regulatory domains [2, 3, 5, 14]. However, developing selective therapies remains challenging due to the high structural homology among PKC isoforms and the potential for systemic toxicity arising from its widespread physiological functions [2, 11]. Clinical trials have explored PKC-α inhibitors for cancer and diabetic complications, though many have faced hurdles regarding efficacy and safety [2, 3, 11]. Monitoring PKC-α activity or expression levels serves as a potential biomarker for disease progression and therapeutic response [15, 16, 17].

Other names

PRKCAPKC-alphaProtein kinase C alpha typeAging-associated gene 6PKCAPKCI+/-

ATP-competitive inhibition, substrate-competitive inhibition, antisense-mediated mRNA degradation, and modulation of regulatory domains (C1/C2) [2, 3, 5, 14].